A growth stock I’d buy alongside this Neil Woodford favourite

Top investor Neil Woodford has a nose for major growth stocks, and you can follow his lead.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

In some ways, I see upcoming pharmaceuticals and biotechnology companies as being very similar to oil and gas explorers. They’re risky and some will surely fail, but if you spread your money across a selection of them, you really only need one or two to come good and you could be nicely in profit.

That seems to be Neil Woodford’s approach as he holds a decent handful of them in his CF Woodford Equity Income Fund, in addition to big pharmaceutical stocks like the fund’s top holding, AstraZeneca.

One of them is BTG (LSE: BTG), which develops products targeting critical care, cancer, neurological and other disorders. 

BTG shares went through a rapid growth phase in the couple of years leading up to the end of 2014, in what looked like a classic growth-share pile-on. Since a peak of around 830p, the shares went into a slide, as often happens. They’ve picked up again, but at 752p as I write they’re still down after nearly three years — and investors have had no dividends as compensation.

Strong forecasts

But I like the look of BTG now, and I think we’re seeing an attractive growth valuation. From a P/E that exceeded 45 in early 2015, we’re now looking at a more reasonable forward multiple of 24 based on March 2018 forecasts, dropping to 21 a year later. That’s higher than the FTSE averages, but I think not bad for a company with double-digit earnings per share growth on the cards.

A pre-close update reported “a good performance in the first half of the year,” with produce sales growth in double-digits at constant exchange rates — and expected sales growth looked good across all product divisions.

Interim results are due on 14 November. The company is still in a phase of investing its strong cash flow in expansion and pipeline development, but I’ll be keen to see if there’s any word on future dividends.

Blue sky potential

Certainly riskier, but with possibly great potential, is Oncimmune Holdings (LSE: ONC), which is developing early cancer detection.

With a current market capitalisation of £59m, it only floated on AIM in May 2016 and is still in its cash-burn phase, so it’s not for the faint-hearted. The year to May 2016 saw a pre-tax loss of £9m — but that should fall this year, and in September 2017 the firm raised an additional £5m through a share placing.

That should leave it on a comfortable financial footing for now — but further fundraising does seem inevitable before the company achieves profitability.

European expansion

It could be one step closer to that, having just signed a distribution agreement with SmartGene of Poland for its EarlyCDT-Lung test. The deal covers “screening and indeterminate pulmonary nodule applications” and has a minimum sales commitment of around £900,000 over an initial term of three years — first sales should start in early 2018.

Poland, with more than 10m smokers and over 1m CT scans performed annually, apparently has the highest incidents of lung cancer in Europe, and is seen by Oncimmune as a key market.

On top of three existing distribution agreements, the firm now has committed sales of £1.4m, and chief executive Geoffrey Hamilton-Fairley says he expects more agreements to be signed in the coming months.

Full-year results are due on 20 October, and any hint of when profit might be expected would be welcomed.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and BTG. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Will it be too late to buy Nvidia stock in March?

NVIDIA stock is up more than 60% since the start of 2024. Our writer considers whether it might still be…

Read more »

Typical street lined with terraced houses and parked cars
Investing Articles

Why did Direct Line shares just soar 27%?

Direct Line shares have jumped more than a quarter in the course of today's trading session. Our writer explains why…

Read more »

Close-up of British bank notes
Investing Articles

These 2 shares are Dividend Aristocrats. Which should I buy this March?

Our writer likes the business model of this pair of FTSE 100 Dividend Aristocrats. So why would he only consider…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Investing Articles

I bought 49 Unilever shares in June. Here’s what they’re worth today

Harvey Jones bought a modest amount of Unilever shares last summer hoping the stock would soon recover. He's having to…

Read more »

BUY AND HOLD spelled in letters on top of a pile of books. Alongside is a piggy bank in glasses. Buy and hold is a popular long term stock and shares strategy.
Investing Articles

I reckon these shares, potentially 20% undervalued, are Warren Buffett’s type of investment

Oliver Rodzianko thinks Games Workshop is an absolutely stellar investment. As it's potentially undervalued, he reckons Warren Buffett would agree.

Read more »

Calendar showing the date of 5th April on desk in a house
Investing Articles

Great investing habits that can boost my Stocks and Shares ISA

Forget complicated calculations and financial jargon! Our writer uses a few simple habits to build wealth inside his Stocks and…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

Why has the St. James’s Place share price crashed 30%, after FY results?

The St. James's Place share price has just fallen off a cliff. What could have gone wrong in 2023 that's…

Read more »

Family in protective face masks in airport
Investing Articles

Here’s how much I’d have if I’d bought 1,000 Rolls-Royce shares 10 years ago

Rolls-Royce shares may be flying high this year but that wasn't always the case. I'm calculating how much I'd have…

Read more »